Sanofi Poised for Swift Medivation Move as Earnings DropBy
Second-quarter profit drops 8.7% as Plavix, Lantus decline
Drugmaker maintains forecast for stable earnings in 2016
Sanofi said it’s ready to act swiftly to reach a deal with U.S. biotechnology company Medivation Inc. as profit and sales declined, highlighting the need for new medicines to propel growth.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.